Advanced search
Publication Cover
Ocular Immunology and Inflammation Latest Articles
Submit an article Journal homepage
196
Views
0
CrossRef citations to date
0
Altmetric
Brief Report

Intra-Ocular Inflammation and Occlusive Retinal Vasculitis Following Intravitreal Injections of Faricimab: A Case Report

Xiuju ChenRetina Department, Xiamen Eye Center, Xiamen University, Xiamen, ChinaView further author information
, MD,
Xiaobo WangRetina Department, Xiamen Eye Center, Xiamen University, Xiamen, ChinaView further author information
, MD &
Xiaoxin LiRetina Department, Xiamen Eye Center, Xiamen University, Xiamen, ChinaCorrespondence[email protected]
View further author information
, MD, PhD
Received 02 Apr 2024, Accepted 27 May 2024, Published online: 10 Jun 2024

References

  • Heier JS, Khanani AM, Ruiz CQ, Basu K, Ferrone PJ, Brittain C, et al. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials. Lancet. 2022;399(10326):729–740. doi: 10.1016/S0140-6736(22)00010-1.
  • Wykoff CC, Abreu F, Adamis AP, Basu K, Eichenbaum DA, Haskova Z, et al. Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised, double-masked, phase 3 trials. Lancet. 2022;399(10326):741–755. doi: 10.1016/S0140-6736(22)00018-6.
  • Momenaei B, Wang K, Kazan AS, Oh GJ, Ni RL, Wakabayashi T, et al. Rates of ocular adverse events after intravitreal faricimab injections. Ophthalmol Retina. 2024;8(3):311–313. doi: 10.1016/j.oret.2023.12.001.
  • Jabs DA, Nussenblatt RB, Rosenbaum JT. Standardization of uveitis nomenclature for reporting clinical data. Results of the first international workshop. Am J Ophthalmol. 2005;140(3):509–516. doi: 10.1016/j.ajo.2005.03.057.
  • Agarwal A, Afridi R, Agrawal R, Do DV, Gupta V, Nguyen QD. Multimodal imaging in retinal vasculitis. Ocul Immunol Inflammation. 2017;25(3):424–433. doi: 10.1080/09273948.2017.1319494.
  • Agarwal A, Rübsam A, Zur Bonsen L, Pichi F, Neri P, Pleyer U. A comprehensive update on retinal vasculitis: etiologies, manifestations and treatments. J Clin Med. 2022;11(9):2525. doi: 10.3390/jcm11092525.
  • Hussain RM, Neiweem AE, Kansara V, Harris A, Ciulla TA. Tie-2/Angiopoietin pathway modulation as a therapeutic strategy for retinal disease. Expert Opin Investig Drugs. 2019;28(10):861–869. doi: 10.1080/13543784.2019.1667333.
  • Khanani AM, Aziz AA, Khan H, Gupta A, Mojumder O, Saulebayeva A, et al. The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study–6 month results. Eye. 2023;37(17):3574–3581. doi: 10.1038/s41433-023-02553-5.
  • Penha FM, Masud M, Khanani ZA, Thomas M, Fong RD, Smith K, et al. Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME. Int J Retin Vitr. 2024;10(1):5. doi: 10.1186/s40942-024-00525-9.
  • US Food and Drug Administration. Highlights of Vabysmo prescribing information. https://wwwaccessdatafdagov/drugsatfda_docs/label/2022/761235s000lblpdf. Accessed January 2, 2024.
  • Palmieri F, Younis S, Bedan Hamoud A, Fabozzi L. Uveitis following intravitreal injections of faricimab: a case report. Ocul Immunol Inflammation. 2023:1–5. doi: 10.1080/09273948.2023.2293925.
  • Thangamathesvaran L, Kong J, Bressler SB, Singh M, Wenick AS, Scott AW, et al. Severe intraocular inflammation following intravitreal faricimab. JAMA Ophthalmol. 2024;142(4):365. doi: 10.1001/jamaophthalmol.2024.0530.
  • Baumal CR, Spaide RF, Vajzovic L, Freund KB, Walter SD, John V, et al. Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab. Ophthalmology. 2020;127(10):1345–1359. doi: 10.1016/j.ophtha.2020.04.017.
  • Jain A, Chea S, Matsumiya W, Halim MS, Yaşar Ç, Kuang G, et al. Severe vision loss secondary to retinal arteriolar occlusions after multiple intravitreal brolucizumab administrations. Am J Ophthalmol Case Rep. 2020;18:100687. doi: 10.1016/j.ajoc.2020.100687.
  • Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Regillo CD, et al. Understanding retinal vasculitis associated with brolucizumab: complex pathophysiology or Occam’s razor? Ocul Immunol Inflammation. 2022;30(6):1508–1510. doi: 10.1080/09273948.2021.1897628.
  • Sharma A, Kumar N, Parachuri N, Bandello F, Kuppermann BD, Loewenstein A. Faricimab: two in the bush is proving better than one in the hand? Ocul Immunol Inflammation. 2022;30(7–8):1961–1963. doi: 10.1080/09273948.2021.1931350.
  • Sharma A, Kumar N, Parachuri N, Singh S, Bandello F, Kuppermann BD, et al. Brolucizumab-related retinal vasculitis: emerging disconnect between clinical trials and real world. Eye. 2021;35(5):1292–1294. doi: 10.1038/s41433-020-01227-w.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.